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T2-weighted MRI detects presymptomatic pathology in the SOD1
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and Nicola R Sibson2
Neuroinflammation has been identified as a potential therapeutic target in amyotrophic lateral sclerosis (ALS), but relevant
biomarkers are needed. The superoxide dismutase (SOD1)G93A transgenic mouse model of ALS offers a unique opportunity to study
and potentially manipulate presymptomatic pathology. While T2-weighted magnetic resonance imaging (MRI) has been shown to
be sensitive to pathologic changes at symptom onset, no earlier biomarkers were previously identified and the underlying
histopathologic correlates remain uncertain. To address these issues, we used a multimodal MRI approach targeting structural
(T2, T1, apparent diffusion coefficient (ADC), magnetization transfer ratio (MTR)), vascular (gadolinium diethylene triamine pentaacetic
acid), and endothelial (vascular cell adhesion molecule–microparticles of iron oxide) changes, together with histopathologic
analysis from presymptomatic to symptomatic stages of disease. Presymptomatic changes in brainstem nuclei were evident on
T2-weighted images from as early as 60 days (Po0.05). Histologic indices of vacuolation, astro- and microglial activation all
correlated with T2-weighted changes. Significant reductions in ADC (Po0.01) and MTR (Po0.05) were found at 120 days in the
same brainstem nuclei. No changes in T1 relaxation, vascular permeability, or endothelial activation were found at any stage of
disease. These findings suggest that T2-weighted MRI offers the strongest biomarker potential in this model, and that MRI has
unique potential for noninvasive and longitudinal assessment of presymptomatically applied therapeutic and neuroprotective
agents.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegen-
erative disorder characterized pathologically by a progressive loss
of upper motor neurons of the corticospinal tract and lower motor
neurons of brainstem nuclei and ventral roots of the spinal cord.
There is currently no treatment to reverse progression, and the
median survival from symptom onset is 2 to 4 years.1
The best characterized and most consistent model of ALS is the
transgenic rodent overexpressing mutant forms of the human
Cu/Zn superoxide dismutase (SOD1) gene, in particular SOD1G93A.2
Superoxide dismutase mice have a predictable disease
progression and pathology, and uniquely recapitulate some of
the core clinical features of the human disorder.3 The SOD1G93A rat,
being larger, might offer advantages for magnetic resonance
imaging (MRI) but has been less well characterized.
The capacity of the SOD1G93A mouse model to successfully
deliver disease-modifying agents that have positive effects on
symptomatic human ALS has been disappointing, but its unique
window on presymptomatic pathologic events has the potential
to inform future neuroprotective therapeutic trials. The need for
an optimized and standardized framework for such animal studies
is now recognized.4
In addition to survival, slowing of the decline in motor function
is currently the primary biomarker in such trials. The rotarod
apparatus is typically used to measure symptom onset and
progression,5 and is traditionally an important marker when
evaluating the effectiveness of drugs. However, symptoms only
become apparent with this approach when the underlying
pathology is significantly advanced, and behavioral tests are
necessarily only sensitive to function of specific neuronal
populations. Magnetic resonance imaging in contrast offers
unique potential to noninvasively provide information about
underlying pathologic changes that occur in all regions of the
central nervous system before, during, and after the onset of
symptoms.6
While it is established that T2 MRI is sensitive to tissue changes
around the time of symptom onset in SOD1 mice,7–9 it is not yet
clear which aspects of pathology are measured by this technique,
although vacuolation is a hypothesis.8 Moreover, MRI indices of
presymptomatic pathology have yet to be identified, and work
with other MRI approaches is relatively scarce and largely
restricted to diffusion-weighted MRI.7,10 Nonimaging studies
have shown vascular alterations at the blood–brain barrier (BBB)
in SOD1 mouse models, including increased permeability and
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vascular activation.11–13 Similarly, MRI studies in the SOD1G93A rat
model using the contrast agent gadolinium diethylene triamine
pentaacetic acid (Gd-DTPA) have shown increased BBB permea-
bility in the midbrain/interbrain region.14,15 At the same time,
cellular adhesion molecules such as vascular cell adhesion
molecule 1 (VCAM-1) that are upregulated during endothelial
activation can be tracked in vivo using MRI by conjugation of
appropriate antibodies to microparticles of iron oxide (MPIO).16,17
However, neither of these contrast agent approaches have yet
been applied in transgenic mouse models of ALS.
The aim of this study was to use a multimodal MRI approach,
including T1 (with and without Gd-DTPA), T2, T2* (with VCAM-
MPIO), apparent diffusion coefficient (ADC), and magnetization
transfer ratio (MTR), together with histologic assessment of
pathology, to determine their potential as early and sensitive
biomarkers for ALS disease progression, and to characterize the
histologic substrate of the magnetic resonance changes observed.
MATERIALS AND METHODS
Mice
Transgenic mice carrying a mutation in the human SOD1 gene derived
from the B6SJL-TgN (SOD1G93A) model from the Jackson Laboratories
(Bar Harbor, ME, USA) were used. The line was maintained by mating
transgenic male mice with wild-type (WT) B6SJL mice, acquired from
Harlan Laboratories (Bicester, UK). Mice were housed in individually
ventilated cages, and given food and water ad libitum. All animal
experiments were approved by the University of Oxford local animal
ethical committee, and performed according to terms of a license granted
by the UK Home Office (License number 30/2533), adhering to the Animals
(Scientific Procedures) Act 1986. Female SOD1G93Aþ / mice were used as
the experimental group and female WT (SOD1G93A / ) littermates were
used as a control group. This allowed all male SOD1G93Aþ / to be used to
maintain the colony.
Behavioral Assessments
Mice were tested on the rotarod (Ugo Basile, Comerio, Italy) at 40, 60, 80,
100, and 120 days, measuring time taken to fall off the apparatus. A larger
sample (N¼ 10) in each group was used for behavioral measurements
(including the mice used for the MRI study), to increase the study power.
Mice were also weighed just before each behavioral session. The
combination of these two methods allowed assessment of symptom onset.
Magnetic Resonance Imaging
Monoclonal antibodies to VCAM-1 (clone M/K2; Cambridge Bioscience,
Cambridge, UK) were conjugated to myOne tosylactivated MPIO (1mm
diameter; Invitrogen, Carlsbad, CA, USA), as described previously.16
Female SOD1G93A and female WT littermates in each group were
scanned once only, and euthanized immediately after the MRI to allow
histologic analysis. Magnetic resonance imaging was performed using a
7-T superconducting magnet driven by a Varian DirectDrive spectrometer
(Varian Inc., subsidiary of Agilent Technologies, Santa Clara, CA, USA) at 40,
60, 80, 100, and 120 days (N¼ 4 in each group, at each time point). Mice
were anesthetized by inhalation of 1.5% isoflurane with 30% O2 and 70%
N2, and placed in a quadrature radio frequency coil with tooth bar and
head restraint to reduce motion artifact. Respiration was monitored
throughout and body temperature was maintained at 371C.
For detection of VCAM-MPIO, a T2*-weighted 3D gradient echo data set
was acquired as follows: flip angle¼ 271; repetition time (TR)¼ 65ms; echo
time (TE)¼ 7.5ms; field of view¼ 22.5mm 22.5mm 11.25mm; matrix
size¼ 256 192 96; averages¼ 2; total acquisition time ca. 40minutes.
The midpoint of acquisition was 1.5 hours after MPIO injection (4mg Fe/kg
body weight in 100mL saline, intravenously). Data were zero-filled to 256
256 128 and reconstructed off-line, giving a final isotropic resolution of
88mm.
Following, a fast spin-echo multislice sequence (T2-weighted) was acquired
spanning the brain and the brainstem: TR¼ 3,000ms; TE¼ 61.9ms; field of
view¼ 25 25mm; matrix size¼ 256 256; ns¼ 13; averages¼ 2; slice
thickness¼ 1mm; acquisition time¼ 3minutes 12 seconds.
Subsequently, T1-weighted images were acquired using a spin-echo
sequence (TR¼ 500ms; TE¼ 20ms; field of view¼ 25mm 25mm; matrix
size¼ 256 256; ns¼ 11; averages¼ 2; slice thickness¼ 1mm; acquisition
time¼ 4minutes 16 seconds) both pre-Gd-DTPA and 5minutes post-Gd-
DTPA (Omniscan; GE Healthcare, Chalfont, UK) injection (30mL; intrave-
nously) to identify BBB permeability, as described previously.18,19 Soft
tissues in the head were examined to confirm proper delivery of Gd-DTPA,
which extravasates rapidly into these tissues.
In a separate group of SOD1G93A and WT mice (N¼ 5 per group), T2-
weighted (as above), diffusion-weighted, and magnetization transfer data
were acquired at 120 days. Diffusion-weighted images were acquired using
a navigated pulsed-gradient spin-echo sequence (TR¼ 2.0 seconds;
TE¼ 35.1ms; matrix size¼ 128 128; average¼ 1; slice thickness¼ 1mm;
ns¼ 11; total acquisition time¼ 12minutes 48 seconds each), with
diffusion-weighting b values of 125, 500, and 1,000 s/mm2, a diffusion
gradient duration of 12.5 seconds, gradient separation of 17.5ms and
gradient amplitude of 8.19G/cm. Diffusion gradients were applied sepa-
rately along three orthogonal axes and ADC ‘trace’ maps were calculated.
To obtain MTR maps, spin-echo images were acquired (TR¼ 4.5 seconds;
TE¼ 13.8ms; hard magnetization transfer pulse length¼ 384ms; offset
frequency¼  1,500Hz; field of view¼ 25 25mm; matrix size¼ 128
 128; ns¼ 11; average¼ 1; slice thickness¼ 1mm) with and without the
magnetization transfer saturation pulse (total acquisition time¼ 9minutes
35 seconds each scan).
Magnetic Resonance Imaging Analysis
All acquisition, processing, and calculations were performed in VNMRJ
(Agilent Technologies) unless otherwise specified. For analysis of the 3D
T2* data, whole brain, cortex, and brainstem regions were segmented
using ITK snap (http://www.itksnap.org/pmwiki/pmwiki.php). Within each
of these regions, the number of hypointensities was calculated using
Matlab (Mathworks Inc., Natick, MA, USA). Hypointensities were calculated
as those voxels that were o65% of the mean signal intensity of all voxels
in the tissue, and a cutoff of 20 contiguous voxels was used to omit larger
structures (e.g., sinuses). By dividing the number of hypointensities by the
number of voxels in the mask, the percentage of hypointense voxels per
brain was calculated.
For T1 data sets, the pre-Gd-DTPA image was subtracted from the post-
Gd-DTPA image, and expressed relative to the pre-Gd-DTPA image. For T1-
and T2-weighted images, and ADC and MTR maps, circular regions of
interest (ROIs) were placed over the three motor nuclei (MN V, VII, and XII)
in each mouse in native space, as well as a control region on the same
slices as the nuclei (within the brainstem, but outside the nuclei of
interest), and intensities were measured as (ROI control region)/control
region. The ROI size was set to adequately cover the area of hyperintensity
in 120-day SOD1G93A mice, which encompasses the entire area of the
motor nucleus. Diameters were trigeminal, 1.4mm2; facial, 1.2mm2;
hypoglossal, 1.1mm2.
Intracerebral Injections
To obtain positive control tissue for immunohistochemistry and VCAM-1
contrast, mice were microinjected bilaterally with human recombinant
interleukin-1b (IL-1b) (1 ng/mL). Mice were anesthetized as described for
MRI above, and cytokine was stereotactically microinjected over 5minutes
into the sensorimotor cortex (0.5mm anterior and 1.5mm lateral (left and
right) to Bregma, at a depth of 0.75mm from the cortical surface), using a
finely drawn glass microcapillary (Drummand Scientific Company, Broo-
mall, PA, USA). For brain trauma control, the same procedure was
performed with a large bore (23G) needle with no injection of cytokine.
Mice were perfusion fixed (as below) for histology 4 hours after cytokine
injection.
Histology/Immunohistochemistry
Following MRI, mice were killed using pentobarbital (100mL) and
transcardially perfused with heparinized saline followed by transcardial
fixation with 100mL PLPlight (75mmol/L lysine HCl, 10mmol/L disodium
hydrogen orthophosphate, 10mmol/L sodium periodate, 2% paraformal-
dehyde, 0.025% glutaraldehyde). Brains were removed and cut in half
down the midline. One hemisphere was further fixed with 4% paraform-
aldehyde for 24 hours, and then dehydrated through increasing grades of
ethanol (80%, 95%, and 100%), cleared in histoclear and embedded in
paraffin wax. The second hemisphere was further fixed in PLPlight for
4 hours, and then placed in 30% sucrose for cryoprotection. Following
cryoprotection, the tissue was frozen in TissueTek OCT mounting medium
(Bayer Plc, Newbury, UK) using isopentane cooled on dry ice. Wax sections
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were cut at 10mm using a Reichart-Jung microtome (Heidelberg,
Germany). Frozen sections were cut at 10mm using a Leica CM1850
cryostat (Leica Microsystems, Milton Keynes, UK).
Sections through the brainstem nuclei were stained with H&E to study
vacuolation (wax sections). In addition, immunohistochemistry was per-
formed using antibodies to glial fibrillary acidic protein (GFAP) (rabbit anti-
GFAP; DAKO, Glostrup, Denmark) for activated astrocytes (wax sections),
ionized calcium-binding adapter molecule 1 (Iba1) (goat anti-Iba1; Abcam,
Cambridge, UK) for activated microglia (wax sections), and VCAM-1 (rat
anti-VCAM-1; Cambridge Bioscience) for vascular activation (frozen
sections). Wax sections were first rehydrated, and subsequently washed
in phosphate-buffered saline (wax and frozen sections). Endogenous
peroxidase activity was quenched using methanol with 0.3% H2O2 for
20minutes, and Fc sites blocked using 10% serum (goat serum for GFAP
and VCAM-1, horse serum for Iba-1) for 1 hour at room temperature.
Primary antibody was diluted in phosphate-buffered saline (1:1,000 for
GFAP, 1:500 for Iba-1, and 1:200 for VCAM-1), and incubated with the tissue
overnight at 41C. Appropriate secondary antibody (Vector Labs, Peterbor-
ough, UK) was added to the tissue 1:100 for 1 hour (goat anti-rabbit IgG for
GFAP, horse anti-goat IgG for Iba-1, aand goat anti-rat IgG for VCAM-1),
followed by Vector elite ABC reagent for 1 hour. All tissue of the same time
point, stained with the same antibody, were processed at the same time
to ensure consistency. Antibody binding was visualized using the
3,30-diaminobenzidine (DAB) reaction, and counterstaining for immuno-
histochemistry was with hematoxylin alone.
Analysis of Histology/Immunohistochemistry
For immunohistochemistry analysis, the three largest cross-sections of
each nucleus were used for consistency (V, VII, and XII), using a  10
objective lens. Nuclei were localized using the Paxinos mouse brain atlas as
a reference.20 Images were then analyzed using the ImageJ software
(National Institute of Health, Bethesda, MD, USA). Color deconvolution was
used to split the brown DAB channel from the blue hematoxylin channel,
and the mean optical density of the DAB stain was measured in a standard
circle with a diameter of 500 units within ImageJ. Optical density (i.e.,
absorbance) is the log ratio of the amount of light being absorbed by the
tissue, and the amount of light passing through. This increases with the
amount of DAB deposition and, therefore, staining intensity. The optical
density measure was then averaged across the three slices through the
nucleus.
For the analysis of vacuolation using H&E-stained tissue, photographs
were taken of the largest three cross-sections of the nuclei using a  10
objective lens using the Paxinos atlas for reference.20 Analysis was also
performed using ImageJ. The background was subtracted, and the image
was binarized to give a value of 0 for normal tissue and 1 for pixels within
vacuoles. An ROI was then drawn around the area of tissue affected by
vacuolation, and the area and the average intensity were measured. From
this, total vacuolation was calculated (area average vacuolation) and
used for analysis.
Statistical Analysis
Sample sizes were chosen based on previous studies, and our experience
with the techniques employed. ANOVA with post hoc t-tests (Hulm–
Bonferroni) was used for comparisons between groups (SPSS, IBM, Armonk,
NY, USA). Effect sizes were compared between MRI sequences using
Cohen’s d, calculated from the mean difference and the standard
deviation. Pearson’s r was calculated for the correlation of T2 hyperintensity
in each brainstem nucleus with (1) quantification of vacuolation, (2) GFAP
staining intensity, and (3) Iba1 staining intensity. To compare correlation
coefficients, r was converted into r’ using Fisher’s transformation, and from
this a z score was calculated for statistical analysis (Microsoft Excel).
RESULTS
Behavioral Data
In keeping with other studies, SOD1G93A mice showed an age-
dependent reduction in motor performance as measured by
rotarod testing, with statistically significant separation from WT
controls at all time points (Po0.05), and a decline in performance
from baseline in SOD1G93A mice at 100 and 120 days (Po0.001).
No significant differences were found within the WT group over
time. Weight data (Figure 1B) showed a similar pattern, with
SOD1G93A mice displaying a significant weight loss compared with
WT littermates at 100 days (Po0.01) and 120 days (Po0.001).
Therefore, using both these measures, symptom onset occurred
between 80 and 100 days of age, consistent with previous reports
of this model.21
T2- and T1-Weighted Magnetic Resonance Imaging
T2-weighted MRI revealed an early and progressive degenerative
change in motor nuclei V (trigeminal), VII (facial), and XII
(hypoglossal) compared with the control brainstem region
(Figure 2). There was significantly more degenerative change as
measured by T2 intensity, in SOD1
G93A compared with WT mice
(V Po0.05; VII Po0.01; XII Po0.001), which increased with disease
progression (V Po0.01; VII Po0.001; XII Po0.01). A significant
difference was evident between SOD1G93A and WT in all three
nuclei at 80 days (V Po0.05; VII Po0.001; XII Po0.05), 100 days
(V Po0.05; VII Po0.01; XII Po0.05), and 120 days (V Po0.05; VII
Po0.01; XII Po0.01), while a difference in the facial nucleus (VII)
was found at the earlier time point of 60 days (Po0.01). At all time
points there was a greater effect size for the difference in T2
intensity between SOD1G93A and WT mice in nucleus VII
(Supplementary Table 1).
In comparison with the T2 signal change, no significant changes
were seen between SOD1G93A and WT mice using T1-weighted
imaging at any time point. Representative images and quantifica-
tion of T1 signal intensity are shown in Supplementary Figure 1.
Comparison of T2, Apparent Diffusion Coefficient, and
Magnetization Transfer Ratio at 120 Days
A second cohort of animals were scanned with T2, MTR, and ADC
sequences at 120 days. As seen in the cross-sectional experiment
above, there was a significant increase in T2 signal intensity at 120
days in all three brainstem motor nuclei (Po0.001) compared with
the control brainstem region (arrows, Figure 3Ai) in SOD1G93A but
Figure 1. Rotarod scores and weights across lifespan for SOD1G93A and wild-type (WT) mice. There was a gradual deterioration in motor score
over time in SOD1G93A, but not in WTmice (A), with a significant reduction from baseline in motor behavior at 100 and 120 days. Weights show
a stereotypical pattern (B), with WT mice increasing in body weight in a linear manner, but the SOD1G93A group becoming significantly lighter
at 100 and 120 days. **Po0.01; ***Po0.001. N¼ 10 in each group. SOD1, superoxide dismutase.
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not in WT mice. For the MTR data, a significant decrease in signal
intensity was found in nuclei V (Po0.05), VII (Po0.01), and XII
(Po0.01) compared with the control brainstem region in SOD1G93A
mice (arrows, Figure 3Aii). Similarly, a significant decrease in ADC
was found in the SOD1G93A group in nuclei V (Po0.001), VII
(Po0.01), and XII (Po0.01). However, for the ADC data, while
changes in nuclei V and VII were apparent by eye in the images
(arrows, Figure 3Aiii) changes in nucleus XII were subtler owing to
artifacts from the nearby ventricle.
Effect sizes were calculated for the difference between
SOD1G93A and WT mice in the three nuclei at 120 days (Supple-
mentary Table 2). T2 changes were associated with a substantially
greater effect size in all three nuclei, particularly the facial nucleus.
The effect size of the MTR and ADC changes was comparable in
the three nuclei, with a marginally greater effect size for MTR in
nucleus XII, and for ADC in nucleus V.
Histologic Analysis of Vacuolation
Mirroring the T2 MRI data, there was a progressive development of
tissue vacuoles over time (Po0.05), in SOD1G93A but not in WT
mice (Po0.05). In nucleus V (Supplementary Figure 2Ai–vi and Bi),
a trend toward increased vacuolation could be seen as early as 60
days (P¼ 0.061), while a significant increase in vacuolation was
found at 80 (Po0.05), 100, and 120 days (Po0.01). In nucleus VII
(Figures 4Ai and 4Bi; Supplementary Figure 2Avii–xii and Bii),
vacuolation also appeared to be increased at 60 days (P¼ 0.079),
reaching significance from 80 days of age (Po0.01; 80, 100, and
120 days). In nucleus XII (Supplementary Figure 2Axiii–xviii and
Biii), a trend toward increased vacuolation was again apparent, but
not significant, at 60 days (P¼ 0.087), and reached significance
from 80 days (Po0.05; 80, 100, and 120 days).
Astrocyte Glial Fibrillary Acidic Protein Immunohistochemistry
For all three nuclei, significantly stronger staining of GFAP was
seen in SOD1G93A compared with WT mice (Po0.01), which
increased over time (Po0.05). Within nucleus V (Supplementary
Figure 3Ai–vi and Ci), there was a trend toward increased GFAP
immunoreactivity at 60 (P¼ 0.059) and 80 days (P¼ 0.084), which
was significantly elevated at 100 days (Po0.01). In nucleus VII
(Figures 4Aii and 4Bii; Supplementary Figure 3Avii–xii and Cii),
GFAP immunoreactivity was significantly increased from 60 to 120
days of age in SOD1G93A compared with WT mice (Po0.01).
A significant increase in GFAP immunoreactivity in nucleus XII
(Supplementary Figure 3Axiii–xviii and Ciii) was evident from 80 to
120 days (Po0.05).
Microglial (Iba1) Immunohistochemistry
As was the case for GFAP, a significant increase in Iba1 staining
was seen in all three nuclei for SOD1G93A compared with WT mice
(Po0.05), which increased over time (Po0.05). For nucleus V
(Supplementary Figure 4Ai–vi and Ci), there was a trend to
increased Iba1 expression in SOD1G93A mice at 80 days (P¼ 0.071),
which was significantly increased at 100 and 120 days (Po0.01). In
both nuclei VII and XII (Figures 4Aiii and 4Biii; Supplementary
Figure 4Avii–xii, Cii, Axiii–xviii and Ciii, respectively), Iba1 staining
was significantly greater from 80 to 120 days of age (Po0.05) in
SOD1G93A mice compared with WT controls.
Correlation of Magnetic Resonance Imaging Changes with
Histologic Measures of Vacuolation and Glial Immunoreactivity
Vacuolation became evident from around the same time as the
increased T2 signal, and increased progressively throughout the
disease in a way that was comparable to T2 signal change (Figures
4Ai, 4Bi, and 4Ci). However, in addition to this, activation of
astrocytes (Figures 4 Aii, 4Bii, and 4Ci) and microglia (Figures 4Aiii,
4Biii, and 4Ci), as shown by an increase in expression of GFAP and
Iba1, respectively, also started from approximately the time of
signal change on T2 MRI, and increased as the disease developed.
These data are shown for the facial nucleus, but are also consistent
with data from the trigeminal and hypoglossal nuclei. Correla-
tional analysis (Figure 4Cii) showed a very high correlation
between all three variables (vacuolation, GFAP, and Iba1) and T2
Figure 2. Comparison of T2 changes in motor nuclei V, VII, and XII in SOD1
G93A and wild-type (WT) mice. Representative T2 images of WT and
SOD1G93A mice at 120 days (A) in nuclei V (left panels), VII (middle panels), and XII (right panels) show a marked signal enhancement in
SOD1G93A mice, compared with surrounding brainstem. Quantification of signal change in the regions of interest (ROIs) compared with
surrounding brainstem region (B) shows an early (60 days in nucleus VII) and progressive increase in signal in SOD1G93A but not in WT mice.
*Po0.05; **Po0.01; ***Po0.001. N¼ 4 in each group. Scale bars represent 1mm. SOD1, superoxide dismutase.
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intensity change, but there was no significant difference between
Pearson’s r for any of the correlations in any of the regions,
showing a similar strength of association.
Magnetic Resonance Imaging indices of Blood–Brain Barrier
Permeability and Vascular Activation
T1 MRI using the contrast agent Gd-DTPA showed no increase in
permeability in the vasculature of any region of the brain, at any
time point of the disease (Figure 5A). This was confirmed by
immunostaining for mouse IgG (Figure 5B). In contrast, significant
mouse IgG immunoreactivity was found in brain trauma-positive
control tissue (Figure 5Bix).
3D T2*-weighted data showed no evidence of VCAM-MPIO
binding at any time point using a whole brain mask (Figure 6), nor
was any increased binding seen when regional analysis was
performed on the brainstem and sensorimotor cortex specifically
(data not shown). Images shown are of the sensorimotor cortex
(Figure 6Aii, left panel) and nucleus VII (Figure 6Aiii, left panel), but
similar results were found in nuclei V and XII (data not shown). In
contrast, IL-1b-injected mice (positive control) showed a high level
of binding (Figure 6Ai, left panel, Figure 6B), especially in the
region of the sensorimotor cortex. Immunohistochemistry for
VCAM-1 was performed in SOD1G93A mice and WT littermates and
confirmed the very low level of VCAM-1 immunoreactivity in
SOD1G93A and WT mice (Figure 6A, right panels), showed very low
immunoreactivity in the sensorimotor cortex, and cranial nuclei at
any point from 40 to 120 days of age. There was also no significant
VCAM immunostaining in WT or SOD1G93A mice in the spinal cord
at any time point (data not shown). However, in a model of
experimental neuroinflammation using IL-1b injected into the
striatum, there was significant VCAM-1 immunoreactivity at and
around the site of injection, confirming the lack of VCAM-1
expression in SOD1G93A mice.
DISCUSSION
This study showed the potential for MRI biomarkers of presympto-
matic, in addition to symptomatic, disease in the SOD1G93A mouse
model of ALS, and explored the histopathologic basis for these
changes. Our findings indicate that T2-weighted MRI is more
sensitive to early pathologic changes than either ADC or MTR MRI,
with SOD1G93A pathology being detected in the facial nucleus as
early as day 60. The MRI changes were accompanied by increased
vacuolation, astrocyte activation, and microglia activation, and all
three of these pathologic variables correlated to the same extent
with the changes found with T2-weighted MRI. No changes in T1
signal intensity were observed at any time point, suggesting that
the changes in T2 signal intensity and ADC were not due to simple
accumulation of tissue fluid, but reflect more complex events. In
contrast to previous reports, no change was found at any time
point in either vascular permeability or endothelial activation,
using both MRI and immunohistochemistry.
T2-Weighted Magnetic Resonance Imaging Changes
This study highlights the potential advantage of using high field
MRI in detecting the earliest pathologic changes in ALS. The
Figure 3. Comparison of T2, magnetization transfer ratio (MTR), and apparent diffusion coefficient (ADC) sequences in SOD1
G93A and control
mice at 120 days. Representative images from T2 (i), MTR (ii), and ADC (iii) sequences (A) showed visible changes in SOD1
G93A mice for all nuclei
(arrows) except for nucleus XII for ADC. Quantification of intensity changes in T2, MTR, and ADC sequences in SOD1
G93A and control mice (B)
indicate that a significant intensity change occurred for all three nuclei in all sequences. Note that intensity change for ADC and MTR has been
inverted for comparison with T2. *Po0.05; **Po0.01; ***Po0.001. N¼ 5 in each group. Scale bar represents 1mm, and applies to all images.
SOD1, superoxide dismutase; ROI, region of interest.
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progressive increase in T2 MRI signal observed in motor nuclei V
(trigeminal), VII (facial), and XII (hypoglossal) in SOD1G93A mice is
consistent with previous studies that showed signal change either
postsymptomatically or immediately before the onset of symp-
toms at 80 days.7,9,10 However, the present study found more
dramatic changes in motor nucleus VII, beginning at 60 days, with
a trend toward changes as early as 40 days. These changes were
seen despite a relatively short scanning time (3minutes
12 seconds) compared with that required for T2 mapping
(77minutes)7 or high-resolution T2 images (42minutes).
9 This
increased sensitivity likely reflects, at least in part, the greater
signal-to-noise achievable with higher field MRI systems, in this
case 7 T compared with 4.7 T used previously.7,9
The more pronounced signal change in nucleus VII is consistent
with previous reports highlighting this region as a focus of
degenerative changes, along with nucleus V.9,22 However, one
previous MRI study did not find any changes in the nucleus XII,9
and a histologic examination only found a trend toward loss of
neurons in this nucleus.22 Results in the present study corroborate
reports that nucleus XII does in fact show a robust pathologic
change, at least in the SOD1G93A model,7 although to a lesser
extent than nuclei V and VII. The reduced effect of pathology in
nucleus XII could be in part due to the nearby ventricle causing
partial volume effects on MRI.
T2 MRI changes have been noted in human ALS. Standard T2
and fluid attenuated inversion recovery (FLAIR) sequences
frequently show increased signal intensity in the corticospinal
tract,23 but they lack sensitivity and specificity.24 However,
standard clinical T2 sequences do not typically show pathology
in the brainstem nuclei, even though pathology can be shown
with other magnetic resonance applications such as
spectroscopy,25 and through histopathologic analysis.26
Histologic Correlates of Magnetic Resonance Imaging Changes
Both astrocytes and microglia underwent morphologic changes
throughout the disease in SOD1G93A mice. The earliest changes were
found from 60 days for astrocytes and 80 days for microglia, and the
protein expression continued to be elevated for the rest of the
disease time course. Similarly, as shown by previous reports,8 early
involvement of vacuole pathology was evident in all three cranial
motor nuclei, in this case starting at 60 days and progressing in a
fairly linear manner as the disease developed. Vacuole pathology,
GFAP immunoreactivity, and Iba1 immunoreactivity were all
significantly correlated with T2 signal change in nuclei V, VII, and
XII, with no significant differences between any of the correlation
coefficients in any of the regions. Previous reports have assumed
that T2 signal change in cranial nuclei is due to the appearance of
vacuoles, based solely on temporal coincidence.8 However, the data
presented here show that any one of these parameters, (tissue
vacuolation, astrocyte activation, and microglia activation), or some
combination of the three might contribute to the MRI signal.
Since the nuclei in question are small structures (nucleus
VII¼B0.85mm diameter at widest point) it is not yet
Figure 4. Relationship between T2 signal change with vacuolation, astrocyte activation (GFAP), and microglia activation (Iba1). Representative
images are shown for vacuolation (H&E) (i), and GFAP (ii), and Iba1 (iii) immunoreactivity in wild type (WT) mice and SOD1G93A throughout the
disease in the facial nucleus (A). Hematoxylin counterstain was used for immunostaining. (B) Quantification of these disease features showing
an increase in vacuolation (i), GFAP staining (ii), and Iba1 staining (iii) in the facial nucleus over from 60/80 days to 120 days. By plotting fold
change in T2 hyperintensity, vacuolation, and GFAP/Iba1 immunoreactivity (Ci), we can see a similar relationship between T2 intensity changes
with all three variables (vacuolation, GFAP, and Iba1). In line with this, there is a high correlation coefficient (Pearson’s r) for the relationship
with T2 intensity change for vacuolation, GFAP immunoreactivity, and Iba1 immunoreactivity in all three cranial nuclei (V, VII, and XII) (Cii), with
no significant difference between the correlation coefficients in each of these regions (P40.05). *Po0.05; **Po0.01, GFAP, glial fibrillary acidic
protein; Iba1, ionized calcium-binding adapter molecule 1; SOD1, superoxide dismutase.
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possible to draw any spatial correlations between the
histopathologic features and MRI signal changes. While GFAP
and Iba1 are constitutively expressed throughout the brain,
the main areas of elevated GFAP expression in SOD1G93A
compared with WT are in the trigeminal, facial, and hypoglossal
nuclei.
Figure 5. No evidence of blood–brain barrier (BBB) breakdown is seen at any time point in SOD1G93A mice. Subtraction of Gadolinium T1
images (A) showed Gd-DTPA signal change in the ventricles in both SOD1G93A and wild-type (WT) mice, but no signal change is seen in the
tissue, either in the sensorimotor cortex (i and ii) or in any of the brainstem motor nuclei (iii–v). No IgG staining was noted at any time point (B)
in WT (i and ii), 40-day SOD1G93A (iii and iv), or 120-day SOD1G93A (v and vi) tissue. Panels i, iii, and v show images from the sensorimotor cortex;
ii, iv, and vi show images from nucleus VII. Similarly even at high magnification, no staining was seen around vessels in SOD1 (viii) or WT (vii)
mice. Panel ix shows a photomicrograph from positive control tissue (experimental brain trauma) as a comparison. No change was seen in the
spinal cord (images not shown). N¼ 4 in each group. SOD1, superoxide dismutase; Gd-DTPA, gadolinium diethylene triamine pentaacetic acid.
Figure 6. Imaging of VCAM-1 expression, and the corresponding immunohistochemistry, in the brains of SOD1G93A mice and wild-type (WT)
controls at 120 days, and positive interleukin-1b (IL-1b)-injected controls. Representative T2* images of the cortex (A ii, left panel) and
brainstem (facial nucleus, A iii, left panel) in SOD1G93A mice at end stage show no binding of VCAM-MPIO. However, significant binding could
be seen after injection of IL-1b (A i, top left), where VCAM-MPIO binding causes signal dropout. This was confirmed by VCAM
immunohistochemistry (A, right panels). Quantification of T2* hypointensities (B) shows that there was a significant VCAM-MPIO binding in
the positive control only, with no significant binding in SOD1G93A or WT mice at any time point. Data presented are for whole brain; analysis
was also performed for the sensorimotor cortex and the brainstem in isolation, but no regional effects were found either (data not shown).
Positive control N¼ 3; SOD1G93A and WT N¼ 4. Scale bar applies to all immunohistochemistry images. VCAM-1, vascular cell adhesion
molecule 1; MPIO, microparticles of iron oxide.
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Discrepancy between T2 and T1 Magnetic Resonance Imaging
Signal Changes
As discussed above, previous studies have attributed T2 changes
to the appearance of water filled vacuolation, which increases
throughout the disease process.8 If these changes were a simple
effect of increased water load on T2 relaxation, then a comple-
mentary change in T1 relaxation would also be expected.
27
However, the data reported here show that this is not the case.
Even at disease end point (120 days), when there is an B15-fold
increase in T2 signal, there is no detectable change in T1 signal
intensity. Thus, either the relationship between water load and T2
relaxation is more complex than previously suggested, or other
pathologic features account for, or contribute to, the signal
change. In support of the latter concept, we have previously
showed a significant correlation between areas of T2 hyperin-
tensity and astrocyte activation in a rat model of delayed type
hypersensitivity central nervous system inflammation, in the
absence of correlated changes in T1 signal intensity.
28
Magnetization Transfer Ratio and Diffusion-Weighted Imaging
Previous studies have shown a reduction in ADC values in both the
brainstem and the spinal cord in SOD1 compared with WT mice.7,29
Consistent with these reports, at 120 days, a decrease in ADC values
was observed in all three cranial motor nuclei. We additionally
report a decrease in the MTR in nuclei V, VII, and XII. While both
ADC and MTR values were significantly different between SOD1 and
WT groups, the effect size was less than for T2 signal change,
suggesting that T2-weighted MRI would be the leading candidate
biomarker of disease progression in SOD1G93A mice. Our findings
are also in line with human studies showing MTR changes in the
posterior limb of the internal capsule and the precentral gyrus.30,31
Similarly, changes in diffusion parameters specifically reduced
fractional anisotropy and increased medial diffusivity in the rostral
corticospinal tracts and central corpus callosum are a core feature
of human ALS.32 T2 imaging, MTR, and diffusion changes have not
been specifically reported in the brainstem nuclei in ALS patients,
despite the pathologic involvement of the hypoglossal nuclei being
common in relation to bulbar weakness in the human disease.
A reduction in ADC indicates restricted tissue diffusion, and has
been suggested to reflect either intracellular oedema33 or hypercel-
lularity owing to glial activation and inflammatory cell recruit-
ment.28 Magnetization transfer ratio measures the transfer of
magnetic resonance signal from protons in water that are
associated with macromolecules to protons in free water. Reduc-
tions in MTR have, therefore, been linked with structural changes in
tissue that changes the ratio of free and bound protons, such as
demyelination,34 or generalized inflammatory processes.18 Thus, it
seems likely that the changes in cell morphology owing to glial
activation may significantly contribute to all three of these MRI
measures (T2, ADC, and MTR). More in-depth experimental para-
digms are needed to determine the influence of these factors
individually on T2, ADC, and MTR signal changes. However, taking all
of the MRI data together, it is hypothesized that a richer combi-
nation of factors affecting tissue diffusion properties underpin MRI
changes, rather than a simple acquisition of excess fluid.
Blood–Brain Barrier Integrity
Blood–brain barrier breakdown (mainly spinal cord),11,13 vascular
damage,12 and tight junction protein downregulation13 have been
reported in molecular studies of SOD1 mice. However, we found
no evidence in any brain region, at any time point, of BBB
compromise to the extent that would allow leakage of either Gd-
DTPA or IgG into the parenchyma of the mouse brain.
There are reports of central nervous system Gd-DTPA leakage
around the midbrain/interbrain region near the lateral ventricle in
the SOD1G93A rat model using MRI.14,15 However, the WT images
were not reported for comparison in that study and, as shown in
the present study, signal increase around the lateral ventricles may
otherwise be overinterpreted. Also, because the Gd-DTPA leakage
in those studies was adjacent to the ventricle, there is the potential
for ‘contamination’ of the signal by the high signal intensity of the
cerebrospinal fluid, and/or from Gd-DTPA in the cerebrospinal fluid
due to a disrupted blood–cerebrospinal fluid barrier.
Other than simple species differences, we also considered
whether a possible cause of the varying results was reduced
exposure to pathogens. There is substantial evidence to suggest
that peripheral inflammation can exacerbate central pathology,35
and certainly the mice in the present study were raised in indivi-
dually ventilated cages with very low risk of systemic infection.
We conclude that, at least for SOD1G93A mice, BBB breakdown
does not appear to be a substantial aspect of pathology.
Vascular Activation
In other neuroinflammatory diseases such as multiple sclerosis,
endothelial activation has been shown to be more sensitive to BBB
change than Gd enhancement.36 In the current study, however,
using both a molecular MRI approach and an immunohistoche-
mistry, no increases in VCAM-1 expression were detected at any
time point in SOD1G93A mice, in whole brain, sensorimotor cortex, or
brainstem region. In contrast, previous studies have shown activa-
tion of other cellular adhesion molecules in SOD1 models, such as
intercellular adhesion molecule (ICAM-1) and melanoma cellular
adhesion molecule (MelCAM).11,37 While it is possible that the
endothelial changes are limited to other cellular adhesion
molecules and do not involve VCAM-1, this is contrary to our
current conception of VCAM-1 as being an integral molecule in the
process of adhesion and diapedesis of peripheral inflammatory
cells.38 We conclude that there is currently no useful role for VCAM-
MPIO as a biomarker in SOD1 ALS.
CONCLUSIONS
T2-weighted MRI is sensitive to presymptomatic pathologic change
in SOD1G93A mice, significantly earlier than previously reported, and
is superior to ADC and MTR as a biomarker of SOD1G93A pathology.
Significant breakdown of the BBB was not a feature of this model,
nor was there any evidence for upregulation of endothelial VCAM-1
expression. Magnetic resonance imaging data using T1, T2, ADC, and
MTR support the hypothesis that complex changes to the diffusion
properties of SOD1G93A brainstem tissue underpin the MRI change,
further supported by the fact that histologic measures of vacuo-
lation, GFAP staining, and Iba1 staining are correlated to a similar
extent with T2 intensity.
The histopathologic changes in human ALS and those of the
SOD1G93A mouse model differ in their focus. Significant evolutionary
differences in the motor system with respect to the descending
tracts,39 whereby the CST is significantly more developed in pri-
mates compared with rodents, are a major factor. Nevertheless, the
consistent predilection of T2 hyperintensities for brainstem nuclei in
the SOD1G93A mouse offers important potential as a pharmacody-
namic biomarker in preclinical therapeutic studies, particularly
neuroprotective agents aimed at the presymptomatic phase, which
is an area of increasing interest in the human disease.40
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